Selected dietary supplements labelled to contain Acacia rigidula have been found to be adulterated with the amphetamine isomer ?-methylphenylethylamine (BMPEA).
Selecte
Photo Credit: FotografiaBasica/Getty Images
d dietary supplements labelled to contain Acacia rigidula have been found to be adulterated with the amphetamine isomer β-methylphenylethylamine (BMPEA).1 This is not, however, a new finding. In 2014 the U.S. Food and Drug Administration (FDA) published on the detection of BMPEA in Acacia rigidula dietary supplements, but failed to warn consumers of the potential danger from the adulterant.2
The compound BMPEA was first synthesized in the early 1930s as a substitute for amphetamines, but, until recently, was treated as a research chemical. It is not found naturally in Acacia rigidula, but is added as an additional (often unlisted) ingredient for its physiological effects even though it has not been evaluated for safety in humans. Dr. Pieter Cohen of Harvard Medical School in Massachusetts, USA, told The Column: “We were aware of the FDA findings and mystified that they had not warned consumers or clarified the legality of these spiked products. We were interested to know what would manufacturers do once the FDA had discovered the stimulant.”
The authors purchased 21 dietary supplements labelled as containing Acacia rigidula online in the USA in 2014, and performed liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analyses. The paper reports that more than half of the samples were adulterated with BMPEA ranging from 8.4% to 31.8% per serving. Although only a small number of supplements were analyzed, making it impossible to know if the BMPEA adulteration is a limited issue, it is concerning that the FDA have not exercised their regulatory power to force manufacturers to remove BMPEA.
In a press release published in response to the study by the Council for Responsible Nutrition,3 Steve Mister, president & CEO, said: “Given FDA’s earlier findings combined with this new study by Dr. Cohen, we urge FDA to take immediate enforcement action against these adulterated products containing BMPEA and the companies illegally spiking these products with this synthetic drug. BMPEA does not appear to be a legitimate dietary ingredient, and therefore its inclusion in a product labelled as a dietary supplement makes the product adulterated under the Dietary Supplement Health & Education Act (DSHEA).” - B.D.
References
1. P.A. Cohen, C. Bloszies, and R. Gerona, Drug Testing and Analysis DOI 10.1002/dta.1793 (2015).
2. R.S. Pawar, E. Grundel, A.R. Fardin-Kia, and J.I. Rader, Journal of Pharmaceutical and Biomedical Analysis88, 457-466 (2014) doi:10.1016/j.jpba.2013.09.012.
3. Council for Responsible Nutrition: Press Release “CRN Asks FDA to Enforce the Law” (Last Accessed 10 April 2015: http://www.crnusa.org/CRNPR15-AsksFDAtoEnforcetheLaw040715.html)
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.